0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial

Dario Giugliano, MD; Raffaele Marfella, MD; Antonio Quatraro, MD; Nicoletta De Rosa, MD; Teresa Salvatore, MD; Domenico Cozzolino, MD; Antonio Ceriello, MD; and Roberto Torella, MD
[+] Article and Author Information

From the University of Naples, Naples, Italy. Requests for Reprints: Dario Giugliano, MD, Via Emilia 1, 80021 Afragola (NA), Italia. Grant Support: In part by a grant from Ministero Pubblica Istruzione.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1993;118(1):7-11. doi:10.7326/0003-4819-118-1-199301010-00002
Text Size: A A A

Objective: To evaluate the effectiveness and safety of tolrestat, an aldose-reductase inhibitor, in patients with mild diabetic autonomic and peripheral neuropathy.

Design: Randomized, placebo-controlled, double-blind 52-week trial.

Setting: University hospital clinic.

Patients: Forty-five diabetic patients with asymptomatic autonomic neuropathy identified by at least one pathologic cardiovascular reflex test result.

Interventions: All patients were given placebo during a 4-week run-in period (single-blind). Twenty patients were randomly assigned to continue to receive placebo, and 25 were assigned to treatment with tolrestat (200 mg/d given in the morning).

Measurements and Results: At 12 months, improvements in nerve functions occurred in patients receiving tolrestat. Compared with baseline values, postural hypotension decreased by a value of 5.9 mm Hg (95% CI, 1.6 to 8.7); deep-breathing, maximum/minimum heart rate (expiration/inspiration ratio) increased by a value of 0.026 (CI, 0.015 to 0.036); and lying-to-standing heart rate ratio (30:15 ratio) increased by a value of 0.032 (CI, 0.027 to 0.052). In the placebo group, all test results except postural hypotension deteriorated. Vibration perception threshold at the malleolus and great toe of the dominant leg improved in the tolrestat group (−1.4; CI, −3.69 to −1.09) but tended to worsen in the placebo group during the study period. No important side effects were detected in either group.

Conclusions: The progression of mild diabetic autonomic and peripheral neuropathy may be halted or even reversed by pharmacologic intervention with the aldose-reductase inhibitor tolrestat.

Figures

Grahic Jump Location
Figure 1.
Individual values of the four cardiovascular reflex tests.Top.Bottom.

In the basal state (Basal) and after 12 months of treatment with the aldose-reductase inhibitor tolrestat. Patients are non–insulin-dependent diabetics; means (SD) of the basal and post-treatment values are represented by a larger filled circle. Individual values of the four cardiovascular reflex tests in 20 non–insulin-dependent diabetic patients assigned to the placebo treatment. The units of measurement for deep breathing are for expiration/inspiration ratio; for lying-to-standing, 30/15 ratio; and for Valsalva, longest/shortest R-R ratio.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)